Core Viewpoint - A shareholder has filed a securities class action lawsuit against Perrigo Company plc, alleging misrepresentations related to its infant formula business acquired from Nestlé, affecting investors who purchased securities between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Perrigo securities during the specified period [1]. - Defendants are accused of making false statements regarding the infant formula business [2]. - Investors interested in participating as lead plaintiffs must file by January 16, 2026 [3]. Group 2: Legal Representation - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [3].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its infant formula business acquired from Nestlé [1][3]. Company Overview - Perrigo provides over-the-counter health and wellness solutions and acquired Nestlé's Gateway infant formula plant and the rights to the Good Start® brand for $170 million in November 2022 [2]. Allegations of Misleading Statements - The lawsuit alleges that Perrigo failed to disclose significant underinvestment in the acquired infant formula business, which required substantial capital expenditures beyond initial estimates to address operational deficiencies [3]. - Specific allegations include manufacturing deficiencies and overstated financial results, including earnings and cash flow [3]. Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, leading to a 50% decline in earnings per share compared to the previous year [4]. - Following this announcement, Perrigo's stock price fell over 15% [4]. - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, and a gross margin decline of 90 basis points, resulting in a nearly 10% drop in stock price [5]. - On August 6, 2025, adjusted gross profit decreased by $30 million (6.9%), with a reported gross margin of 34.4%, causing an over 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, leading to a more than 25% drop in stock price [7]. Legal Process - Investors who purchased Perrigo securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8][9].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the acquisition and performance of its infant formula business [1][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchased between February 27, 2023, and November 4, 2025, with a deadline of January 16, 2026, for potential lead plaintiffs to come forward [1]. - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant for $170 million was plagued by significant underinvestment and operational deficiencies [3][4]. - Specific allegations include the need for substantial capital expenditures beyond initial estimates, significant manufacturing deficiencies, and overstated financial results [4]. Group 2: Financial Impact and Stock Performance - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, leading to a 50% decline in earnings per share compared to the previous year [5]. - Following a report on May 7, 2024, net sales dropped to $91 million, a decrease of 34.5%, attributed to lower shipments during remediation efforts, causing a nearly 10% drop in stock price [6]. - On August 6, 2025, Perrigo reported a $30 million decrease in adjusted gross profit, a 6.9% decline, and a gross margin drop to 34.4%, resulting in an over 11% decline in stock price [7]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, which led to a more than 25% drop in stock price [8].

Core Insights - Class actions have been initiated on behalf of stockholders of Skye Bioscience, Inc. and Perrigo Company plc, with deadlines for lead plaintiff petitions set for January 16, 2026 [1][3][7]. Perrigo Company plc - The class period for Perrigo is from February 27, 2023 to November 4, 2025, during which the company allegedly failed to disclose significant issues in its infant formula business acquired from Nestlé, including underinvestment and manufacturing deficiencies [3][4]. - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [4]. - Following the announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share [4]. Skye Bioscience, Inc. - The class period for Skye is from November 4, 2024 to October 3, 2025, during which the company allegedly made materially false statements regarding the effectiveness and prospects of its drug nimacimab [7]. - On October 6, 2025, Skye disclosed that the nimacimab monotherapy did not achieve its primary endpoint in a clinical study, resulting in a stock price decline of $2.85, or 60%, closing at $1.90 per share [7].

Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Perrigo Company plc, alleging that the company misled investors regarding its business operations and financial health during the specified Class Period from February 27, 2023, to November 4, 2025 [1][2]. Allegations - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance [3]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond its stated cost estimates to address issues within the infant formula business [3]. - The lawsuit points out significant manufacturing deficiencies in the facility related to Perrigo's infant formula business [3]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [3]. - The positive statements made by Perrigo regarding its business operations and prospects were claimed to be materially misleading and lacked a reasonable basis [3]. Class Action Participation - Investors who wish to serve as lead plaintiffs in the class action must file their motions with the court by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery; investors can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired securities of Perrigo Company plc between February 27, 2023, and November 4, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding Perrigo's infant formula business acquired from Nestlé [2] Legal Proceedings - Interested parties wishing to serve as lead plaintiff must file papers by January 16, 2026 [3] - Serving as lead plaintiff is not a requirement for sharing in any recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4] - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4]

Core Points - A shareholder class action lawsuit has been filed against Perrigo Company plc, alleging that the company made materially false and misleading statements regarding its infant formula business acquired from Nestlé [1] - The lawsuit claims significant underinvestment in maintenance and operational improvements in the infant formula business, necessitating substantial capital and operational expenditures beyond stated cost estimates [1] - Allegations include significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [1] - The lawsuit asserts that positive statements made by the defendants about the company's business and prospects were materially misleading and lacked a reasonable basis [1] Legal Context - Shareholders who purchased Perrigo shares between February 27, 2023, and November 4, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is January 16, 2026 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Points - A class action has been filed on behalf of investors who purchased or acquired Perrigo Company plc securities between February 27, 2024, and November 4, 2025 [1] - Perrigo Company plc operates in the over-the-counter health and wellness solutions sector, serving markets in the U.S., Europe, and internationally [1]

Core Viewpoint - A securities fraud lawsuit has been filed against Perrigo Company plc by the Law Offices of Frank R. Cruz, indicating potential legal challenges for the company [1] Group 1 - The lawsuit is categorized as a class action, suggesting that it may involve multiple plaintiffs who have suffered losses due to the alleged fraud [1] - The nature of the allegations has not been detailed in the provided content, but the filing indicates serious concerns regarding the company's financial practices [1] - The outcome of this lawsuit could have significant implications for Perrigo's stock performance and investor confidence [1]